Home  /  Resource Library  /  A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study

A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study

Results of study using temsirolimus and bortezomib in relapsed non-Hodgkin. Patients with DLBCL showed the best response.